ホームページへ

トルコで最高の前立腺癌に対する免疫療法医師 - トップ21名の医師

コンテンツはBookimed編集ポリシーを満たし、以下により医学的にレビューされています

Fahad Mawlood

Bulent Karagoz

  • 4.6 優秀 516 レビュー
  • 33年の経験
  • トルコ, イスタンブール, Anadolu Medical Center
  • 腫瘍生物学・免疫学および全身療法(免疫療法・分子標的療法)に関する査読付き論文を40本以上執筆し、トルコ腫瘍内科学会およびEuropean Head & Neck Societyの会員である。

    患者がビュレント・カラゴズ医師を選ぶ理由:

    • アナドル病院と米国の主要医療センターであるジョンズ・ホプキンス・メディシンとの戦略的提携のもと、米国の診療プロトコルに基づいた治療を提供。
    • 腫瘍生物学・免疫学および全身療法(免疫療法・分子標的療法)に関する査読付き論文40本以上を執筆。
    • 元診療部長(GATA)および教授・学科長(Okan大学、トルコ)として、主要医療センターにおける管理・臨床両面での豊富な経験を有する。
    • 乳癌、肺癌、大腸癌などの固形腫瘍を対象に、腫瘍生物学に基づいた最新の治療レジメンを実施。
    • アナドル病院はESMO認定およびJCI認定を取得しており、国際的なプロトコルに従い、多職種チームによる連携のもと、厳格な安全管理のもとで治療を提供。
  • 続きを読む
診察
お問い合わせください
情報

Eda Tanrikulu

  • 4.6 優秀 516 レビュー
  • 21年の経験
  • トルコ, イスタンブール, Anadolu Medical Center
  • エダ・タンルクル医師は、アナドル医療センターにおいて内科腫瘍学および化学療法を専門とし、前立腺癌に対する免疫療法に重点を置いています。

    • 内科腫瘍学の専門医試験においてトルコ国内第3位の成績を獲得
    • 複数の国際臨床試験における研究補助および主任研究者
    • ハイダルパシャ・ヌムネ教育研究病院の内科腫瘍科部門を以前に統括
  • 続きを読む
診察
お問い合わせください
情報

Mustafa Solak

  • 4.6 優秀 217 レビュー
  • 20年の経験
  • トルコ, イスタンブール, Hisar Hospital Intercontinental
  • ハジェテペ大学癌研究所およびMDアンダーソン癌センターでの研修を経て、前立腺癌の免疫療法を専門とする。

    • 前立腺癌、乳癌、肺癌など多様な癌の治療経験を有する
    • 権威あるハジェテペ大学癌研究所でフェローシップを修了
    • テキサス大学MDアンダーソン癌センターで研修を受ける
    • ヒサール・ホスピタル・インターコンチネンタルに勤務
  • 続きを読む
診察
お問い合わせください
情報

Prof. Sezer Sağlam

  • 5 優秀 2 レビュー
  • 27年の経験
  • トルコ, イスタンブール, Gayrettepe Florence Nightingale Hospital
  • Personal Information 

    Sex:  Male

    Born : 1968 

     

    Professional Experience

    Gayrettepe Florence Nigthingale Hospital

    Medical Oncology Department

    Besiktas/Istanbul/Turkey (ongoing)

     

    Education:

    He became Professor (22/April /2016)

    Medical Oncology

     

    Attending Phys.in Gastrointestinal Oncology (January 2005 ,2009)

    Istanbul University Oncology Institue,

    Department of Medical Oncology

     

    Medical Oncology Fellowship (December 2001-December2004)

    Istanbul University, Istanbul Medical Faculty

     

    Hemodialysis Traning (May1996-January1997)

    Istanbul University ,bCerrahpasa Medical Faculty

     

    Internal Medicine Residency (November 1991-November 1996)

    Istanbul University ,bCerrahpasa Medical Faculty

     

    Ege University Medical Faculty (1985-1991)

     

    Professional Experience

    February 1999-November 2001

    Metropolitan Florence Nigthingale Hospital

    American Cancer Center, Gayrettepe/İstanbul

     

    April1997- October 1998

    Bayraktar Dialysis Center

    Güngören/ Istanbul

     

    Membership

    Turkish Medical Oncology Association

    ENET(European Neuroendocrine Tumour Society)

    ESMO

    ASCO

  • 続きを読む
診察
お問い合わせください
情報

Abdullah Sakin

  • 4.5 良い 2 レビュー
  • 19年の経験
  • トルコ, イスタンブール, Medipol Bahçelievler Hospital
  •  

    Experience

    2022 PRIVATE MEDIPOL BAHÇELİEVLER HOSPITAL

     

    2021 - 2021 Prof. Dr. Cemil Taşçıoğlu City Hospital, Medical Oncology Clinic Education Officer

     

    2021 - 2021 Prof. Dr. Cemil Taşçıoğlu City Hospital

     

    2020 - 2021 Yüzüncü Yıl University Faculty of Medicine

     

    2020 - 2021 Head of the Department of Medical Oncology, Yüzüncü Yıl University Faculty of Medicine, Assoc. Dr.  

     

    2018 - 2021 Lecturer - Yüzüncü Yıl University Faculty of Medicine, Head of Medical Oncology Department  

     

    2018 - 2021 Yüzüncü Yıl University Faculty of Medicine

     

    2015 - 2018 University of Health Sciences, Okmeydanı Training and Research Hospital

     

    2015 - 2018 University of Health Sciences, Okmeydanı Training and Research Hospital, Medical Oncology Clinic, Sub-branch assistant

     

    2012 - 2015 Kanuni Sultan Süleyman Training and Research Hospital, Internal Medicine specialist

     

    2012 - 2015 Suleiman the Magnificent Training and Research Hospital,

     

    2008 - 2012 Haseki Training and Research Hospital

     

    2006 - 2008 Kızıltepe No. 3 Health Center General Practitioner.

     

     

    Education

    2018

    İstanbul Okmeydanı Eğitim ve Araştırma Hastanesi, Tıbbı Onkoloji

    2018

    İstanbul Okmeydanı Eğitim ve Araştırma Hastanesi, Tıbbı Onkoloji, İstanbul Okmeydanı Eğitim ve Araştırma Hastanesi, Tıbbı Onkoloji

    2012

    İstanbul Haseki Eğitim ve Araştırma Hastanesi, İç Hastalıkları, İstanbul Haseki Eğitim ve Araştırma Hastanesi, İç Hastalıkları

    2012

    İstanbul Haseki Eğitim ve Araştırma Hastanesi, İç Hastalıkları

    2007

    Uludağ Üniversitesi Tıip Fakültesi, Tıip Fakültesi, Uludağ Üniversitesi Tıip Fakültesi, Tıip Fakültesi

     

  • 続きを読む
診察
お問い合わせください
情報

Sinan Karaaslan

  • 4.6 優秀 516 レビュー
  • 29年の経験
  • 認定:
  • トルコ, イスタンブール, Anadolu Medical Center
  • シナン・カラアスラン医師は、アナドル医療センターにおいて前立腺癌をはじめとする泌尿生殖器系腫瘍を専門とする腫瘍内科の専門医です。

    • 29年の経験 の腫瘍内科における臨床経験
    • イスタンブール大学チェラフパシャ医学部にて専門研修を修了
    • トルコ腫瘍内科学会会員
    • 免疫療法および分子標的治療を専門とする
  • 続きを読む
診察
お問い合わせください
情報

Yesim Yildirim

  • 4.6 優秀 516 レビュー
  • 22年の経験
  • 認定:
  • トルコ, イスタンブール, Anadolu Medical Center
  • イェシム・イルドゥルム教授は、アナドル医療センターにおける前立腺癌の免疫療法を専門とし、22年の経験以上にわたる集中的な腫瘍内科の診療経験を有しています。

    • 欧州臨床腫瘍学会(ESMO)会員
    • 癌治療ハンドブックの共著を含む、80本以上の国際学術論文の著者
    • マウント・バーノン癌センターにてメラノーマおよび腎癌の免疫療法研修を修了
    • ハリチ大学教授として、学術研究と臨床診療を兼務
  • 続きを読む
診察
お問い合わせください
情報

Seref Komurcu

  • 4.6 優秀 516 レビュー
  • 33年の経験
  • 認定:
  • トルコ, イスタンブール, Anadolu Medical Center
  • シェレフ・ケミュルキュ教授は、ECFMG及びESMO認定の乳腺腫瘍専門医であり、20年以上の診療経験を有しています。固形がん、乳がん、大腸がん、肺がんの治療を専門とし、キャリアを通じて教育・研究職を歴任してきました。複数の専門職能団体の会員でもあります。

診察
お問い合わせください
情報

Necdet Uskent

  • 4.6 優秀 516 レビュー
  • 55年の経験
  • トルコ, イスタンブール, Anadolu Medical Center
  • Dr. Uskent is an experienced doctor with 50+ years of practice in the field of lymphoma and other blood malfunctions. He is known for performing the first bone marrow transplant in Turkey, and has also practiced in the USA and UK.
  • 続きを読む
診察
お問い合わせください
情報

Mustafa Serkan Alemdar

  • 4.5 良い 6 レビュー
  • 20年の経験
  • トルコ, アンタルヤ, Medical Park Antalya Hospital Complex
  • Education and Specialization

    • 2006: Kocaeli University Faculty of Medicine
    • 2014: Akdeniz University Faculty of Medicine, Internal Medicine
    • 2018: Akdeniz University Faculty of Medicine, Medical Oncology

    Experience

    • 2006 - 2008: Konya Derebucak District Hospital
    • 2009 - 2015: Akdeniz University Hospital
    • 2015: Antalya Kaş State Hospital
    • 2015 - 2016: İnönü University Faculty of Medicine
    • 2016 - 2021: Akdeniz University Hospital
    • 2021 - 2023: Antalya Training and Research Hospital
  • 続きを読む
診察
お問い合わせください
情報

Tahsin Ozatli

  • 4.3 良い 18 レビュー
  • 2016年の経験
  • トルコ, イスタンブール, Istinye University Liv Hospital Bahcesehir
  • Oncologist
診察
お問い合わせください
情報

Cemil Bilir

  • 前立腺癌に対する免疫療法のリーディング医師
  • 5 優秀 1 レビュー
  • 21年の経験
  • トルコ, イスタンブール, VM Medical Park Pendik Hospital
  • Education & Expertise

    • 1998 to 2004 – Istanbul University, Istanbul Faculty of Medicine
    • 2005 to 2009 – Düzce University, Internal Medicine Specialization
    • 2009 to 2010 – Beytüşşebap State Hospital, Compulsory Internal Medicine Service
    • 2010 to 2013 – Bülent Ecevit University, Medical Oncology Specialization
    • 2013 to 2015 – Recep Tayyip Erdoğan University, Medical Oncology Compulsory Service
    • 2015 to Present – Associate Professor, Recep Tayyip Erdoğan University
    • 2015 to 2021 – Lecturer, Medical Oncology, Sakarya University Faculty of Medicine
    • 2020 to Present – Professor, Sakarya University Faculty of Medicine
    • 2020 to Present – Ph.D. Student, Inorganic Chemistry, Sakarya University

    Experience

    • 2008 – Cleveland Clinic, Rheumatology & Gastroenterology Rotation
    • 2016 to 2017 – Northeastern University, The Center for Pharmaceutical Biotechnology and Nanomedicine, Boston, U.S.

    Professional Memberships

    • TTOD (Turkish Society of Medical Oncology)
    • ASCO (American Society of Clinical Oncology)
    • ESMO (European Society for Medical Oncology)
  • 続きを読む
診察
お問い合わせください
情報

Atakan Topcu

  • 5 優秀 3 レビュー
  • 13年の経験
  • トルコ, イスタンブール, Medipol Acibadem District Hospital
  • Assoc. Prof. Atakan Topçu, M.D., is a medical oncologist at Medipol University and Medipol Acıbadem Regional Hospital. He treats solid tumors, including lung, breast, colorectal, gastric, and neuroendocrine cancers. His work also covers targeted therapies, immunotherapy, geriatric oncology, and cancer-related malnutrition, cachexia, and sarcopenia.

    He has authored more than 50 peer-reviewed papers. Recent work includes a 2024 Frontiers in Medicine study on geriatric syndromes and a 2023 Future Oncology paper on sarcopenia and anxiety in lung cancer. He has also published on the CONUT score in breast cancer and on malnutrition in HER2-negative metastatic gastric cancer.

    Dr. Topçu serves on the Editorial Board of BMC Cancer. He is a member of the Turkish Society of Medical Oncology, ESMO, and the Turkish Geriatrics Society. Education and training: M.D., Uludağ University; residency in Internal Medicine, Marmara University; fellowship in Medical Oncology, Bezmialem Vakıf University.

  • 続きを読む
診察
お問い合わせください
情報

Ercan Ozden

  • 5 優秀 1 レビュー
  • 27年の経験
  • トルコ, イスタンブール, VM Medical Park Pendik Hospital
  • Dr. Ercan Ozden is a specialist in internal medicine and medical oncology. He earned his medical degree and completed his residency at Istanbul University, Cerrahpaşa Faculty of Medicine. He later received a subspecialty in medical oncology at Kocaeli University Faculty of Medicine from 2016 to 2020.

    Dr. Ozden has worked in medical oncology at Şırnak State Hospital. He has also served as an internal medicine specialist at Bağcılar Private Safa Hospital and Küçükçekmece Batı Bahat Hospital. He has extensive clinical experience in both internal medicine and oncology.

  • 続きを読む
診察
お問い合わせください
情報

Nail Paksoy

  • 4.5 良い 2 レビュー
  • 15年の経験
  • 認定:
  • トルコ, イスタンブール, Medipol Bahçelievler Hospital

  • PROFESSIONAL EXPERIENCE

    2011-2012
    Erzurum Koprukoyu State Hospital
    Department: General Medicine

    2012-2017
    Istanbul University Cerrahpaşa Medical Faculty
    Department: Internal Medicine

    06/2017-10/2017
    Istanbul Gaziosmanpasa Taksim Training and Research Hospital
    Department: Internal Medicine

    10/2017-11/2018
    Istanbul University Istanbul Medical Faculty
    Department: Allergy and Immunology Fellowship

    2018/2022
    Istanbul University Oncology Institute
    Department: Medical Oncology Fellowship

    2022-2023
    Tekirdag City Hospital
    Department: Medical Oncology Specialist

    2023-present
    Istanbul Medipol University Medipol Bahcelievler Private Hospital
    Department: Medical Oncology Assoc. Prof.

     

    EDUCATION

    2005-2011
    Medical Education
    Sivas Cumhuriyet University Medical Faculty, Sivas, Turkey

    2012-2017
    Internal Medicine
    Istanbul University Cerrahpaşa Medical Faculty, Department of Internal Medicine, Istanbul, Turkey

    2017-2018
    Allergy-Immunology Fellowship
    Istanbul University Istanbul Medical Faculty
    Department of Internal Medicine, Division of Allergy and Immunology, Istanbul, Turkey

    2018-2022
    Medical Oncology Fellowship
    Istanbul University Oncology Institute, Department of Medical Oncology, Istanbul, Turkey

    2022
    ESMO Board Certification in Medical Oncology
    10th September 2022 in Paris, France.

    2023
    Medical Oncology Assoc. Prof.
    Istanbul Medipol University Department of Medical Oncology, Istanbul, Turkey

     

    INTERNATIONAL CLINICAL TRIALS:

    1. Astefania - ROCHE

    • Title: A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
    • Role: Subinvestigator

    2. PFİZER

    • Title: A Study Of Lorlatinib Versus Crizotinib In First-Line Treatment Of Patients With ALK-Positive NSCLC
    • Role: Subinvestigator

    3. RECITE - AMGEN

    • Title: Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer
    • Role: Subinvestigator

    4. NAVIGATE - BAYER

    • Title: A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors
    • Role: Subinvestigator

    5. RUBY - Tesaro (PRA)

    • Title: A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Patients With Recurrent or Primary Advanced Endometrial Cancer
    • Role: Subinvestigator

    6. ENGOT-ov43/GOG-3036 - MSD

    • Title: Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK001/ENGOT-ov43/GOG-3036)
    • Role: Subinvestigator

    7. ASTRA ZENECA

    • Title: To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients.
    • Role: Subinvestigator

    8. ROSY-O - ASTRA ZENECA

    • Title: Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib
    • Role: Subinvestigator
    •  

    INTERNATIONAL PUBLICATIONS

    I. Published journal articles indexed by SCI, SSCI, and AHCI

    Weekly Paclitaxel in Classic Kaposi Sarcoma

    • Authors: Paksoy, N., Khanmammadov, N., Doğan, İ., Ferhatoğlu, F., Ahmed, M. A., Karaman, S., & Aydiner, A.
    • Journal: Medicine, 102(5)

    Carboplatin Desensitization in Ovarian Carcinoma

    • Authors: Paksoy, N., Khanmammadov, N., Doğan, İ., Ferhatoğlu, F., Yildiz, A., Ak, N., & Aydiner, A.
    • Journal: Medicine, 101(45), e31726

    High-Dose Chemotherapy for Ewing’s Sarcoma

    • Authors: Paksoy, N., Ferhatoglu, F., Dogan, İ., Khanmammadov, N., Celik, A. I., Gulbas, Z., & Başaran, M.
    • Journal: Medicine, 101(49), e32213

    Multidrug Refractory TFE3(+) Renal Cell Carcinoma

    • Authors: Paksoy, Nail, et al.
    • Journal: Journal of Oncology Pharmacy Practice, 2022, 28.1: 215-221

    Crizotinib Efficacy in NSCLC with MET Alterations

    • Authors: Gürbüz, M., Kiliçkap, S., Bilici, A., Karadurmuş, N., Sezer, A., Şendur, M. A. N., ... & Demirkazik, A.
    • Journal: Medicine, 101(50), e32368

    Clinicopathological Features in ALK Mutant NSCLC

    • Authors: Dogan, I., Gurbuz, M., Paksoy, N., Ferhatoglu, F., Vatansever, S., Saip, P., ... & Aydiner, A.
    • Journal: Medicine, 101(34)

    PSMA-Based Tumor Burden in Prostate Cancer

    • Authors: HAS SIMSEK, Duygu, et al.
    • Journal: Annals of Nuclear Medicine, 2021, 35.6: 680-690

    Atezolizumab in Metastatic Urothelial Carcinoma

    • Authors: TURAL, Deniz, et al.
    • Journal: European Urology Focus, 2021, 7.5: 1061-1066

    Pulmonary Sarcomatoid Carcinoma

    • Authors: FERHATOGLU, Ferhat, et al.
    • Journal: Oncology Research and Treatment, 2021, 44.11: 590-601

    Prognostic Factors in Atezolizumab-Treated Urothelial Carcinoma

    • Authors: TURAL, Deniz, et al.
    • Journal: International Journal of Clinical Oncology, 2021, 26.8: 1506-1513

    Atezolizumab with Chemotherapy in Small Cell Lung Cancer

    • Authors: GÜRBÜZ, Mustafa, et al.
    • Journal: Journal of Cancer Research and Clinical Oncology, 2022, 1-9

    FOLFIRINOX vs. Gemcitabine + Nab-Paclitaxel in Pancreatic Cancer

    • Authors: AY, Seval, et al.
    • Journal: Journal of Chemotherapy, 2022, 1-7

    Trastuzumab Emtansine in Older HER2-Positive Breast Cancer Patients

    • Authors: CIL, Ibrahim, et al.
    • Journal: Tumori Journal, 2022, 108.1: 19-25

    Real-Life Efficacy of Osimertinib in Advanced NSCLC

    • Authors: HIZAL, Mutlu, et al.
    • Journal: Journal of Cancer Research and Clinical Oncology, 2022, 148.6: 1501-1508

    ALK-Positive Cells Percentage and Alectinib Efficacy

    • Authors: Hizal, M., Bilgin, B., Paksoy, N., Atcı, M. M., Kahraman, S., Kılıçkap, S., ... & Şendur, M. A. N.
    • Journal: Journal of Cancer Research and Clinical Oncology, 149(8), 4141-4148

    Real-World Data on Alectinib in ALK-Positive NSCLC

    • Authors: Hizal, M., Bilgin, B., Paksoy, N., Kılıçkap, S., Atcı, M. M., Kahraman, S., ... & Şendur, M. A. N.
    • Journal: Future Oncology, 18(23), 2573-2582

    Prognostic Factors in Metastatic RCC with T790M Mutation

    • Authors: Dogan, I., Iribas, A., Paksoy, N., Vatansever, S., & Basaran, M.
    • Journal: Journal of Cancer Research and Therapeutics

    FLOT Regimen in Metastatic Gastric Cancer

    • Authors: Tastekin, D., Paksoy, N., Dogan, I., Ferhatoglu, F., Khanmammadov, N., Bozbey, H. U., & Karabulut, S.
    • Journal: Journal of Cancer Research and Therapeutics

    Desensitization Protocol in Lenalidomide Hypersensitivity Reactions

    • Authors: DEMIR, Semra, et al.
    • Journal: Annals of Allergy, Asthma & Immunology, 2019, 123.4: 394-397

    Factors Associated with Diagnostic Skin Test Positivity in PPI Hypersensitivity

    • Authors: ÖZDEMIR, Seçil Kepil, et al.
    • Journal: Allergy, 2019, 74.6: 1187-1190

    Efficacy of Capecitabine and Temozolomide in Neuroendocrine Tumors

    • Authors: Ünal, Ç., Azizy, A., Karabulut, S., Taştekin, D., Akyıldız, A., Yaşar, S., ... & Sağlam, S.
    • Journal: The Oncologist, oyad257

    Subsequent Treatments in Hormone-Positive Breast Cancer Progression

    • Authors: Karacin, C., Oksuzoglu, B., Demirci, A., Keskinkılıç, M., Baytemür, N. K., Yılmaz, F., ... & Hacıbekiroğlu, İ.
    • Journal: BMC cancer, 23(1), 192

    Termination of Trastuzumab in HER2-Positive Metastatic Breast Cancer

    • Authors: Dogan, I., Aydin, E., Khanmammadov, N., Paksoy, N., Saip, P., & Aydiner, A.
    • Journal: Scientific Reports, 13(1), 8779

    Long-term Outcomes and Predictors of Recurrence in Node-Negative Early Stage Breast Cancer

    • Authors: Dogan, I., Aydin, E., Khanmammadov, N., Paksoy, N., Ferhatoğlu, F., Ak, N., ... & Aydiner, A.
    • Journal: Journal of Cancer Research and Clinical Oncology, 1-9

    Prognostic Factors Influencing PFS in HER2-Positive Metastatic Breast Cancer

    • Authors: Doğan, İ., Paksoy, N., Ak, N., Vatansever, S., Saip, P., & Aydıner, A.
    • Journal: European Journal of Breast Health, 19(2), 128

    Treatment Efficacy of Ribociclib or Palbociclib plus Letrozole in Metastatic Breast Cancer

    • Authors: Kahraman, S., Erul, E., Seyyar, M., Gumusay, O., Bayram, E., Demirel, B. C., ... & Nahit Sendur, M. A.
    • Journal: Future Oncology, 19(10), 727-736

    Efficacy and Safety of Sorafenib in Adult Metastatic Osteosarcoma Patients

    • Authors: Dogan, I., Paksoy, N., & Basaran, M.
    • Journal: Journal of Cancer Research and Therapeutics

    Single-Agent Temozolomide as Salvage Therapy in Heavily Pretreated Metastatic Sarcoma Patients

    • Authors: Dogan, I., Paksoy, N., & Basaran, M.
    • Journal: Journal of Cancer Research and Therapeutics

    Outcomes and Prognostic Factors in Metastatic Renal Cell Carcinoma with Brain Metastases

    • Authors: Dogan, I., Iribas, A., Paksoy, N., Vatansever, S., & Basaran, M.
    • Journal: Journal of Cancer Research and Therapeutics

    FLOT Regimen in First-Line Treatment of Metastatic Gastric Cancer

    • Authors: Tastekin, D., Paksoy, N., Dogan, I., Ferhatoglu, F., Khanmammadov, N., Bozbey, H. U., & Karabulut, S.
    • Journal: Journal of Cancer Research and Therapeutics

    Prognostic Factors of Perioperative FLOT Regimen in Operable Gastric Cancer

    • Authors: Erol, C., Sakin, A., Basoglu, T., Ozden, E., Cabuk, D., Dogan, M., ... & Sendur, M. A. N.
    • Journal: [Not specified]

    Efficacy and Outcomes of Systemic Chemotherapy in Posttransplant Kaposi Sarcoma

    • Authors: Khanmammadov, N., Paksoy, N., Doğan, I., Ferhatoğlu, F., Saip, P., & Aydiner, A.
    • Journal: Medicine, 102(39), e35383

    Comparison of Second-Line Treatments in Metastatic Renal Cell Carcinoma

    • Authors: Pehlivan, M., Paksoy, N., Aydin, E., Basaran, M., & Ekenel, M.
    • Journal: Medicine, 102(41), e35245

    Toxicity Management and Effectiveness of Regorafenib in Advance GIST Patients: A Real-world Study - Authors: Paksoy, N., Ferhatoğlu, F., Doğan, İ., Khanmammadov, N., Bozbey, H. U., Karabulut, S., & Taştekin, D. - Journal: TURKISH JOURNAL OF ONCOLOGY, 1(1)

    Demographic and Clinical Features and Factors Associated with Survival in Patients with Primary Glomerulonephritis: Single Tertiary Center Experience - Authors: Paksoy, N., Trabulus, S., Seyahi, N., & Altiparmak, M. R. - Journal: Namik Kemal Tip Dergisi, 11(1)

    Efficacy of Sorafenib in Symptomatic Patients with Pretreated Progressive Desmoid Tumors - Authors: Paksoy, N., Ferhatoglu, F., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M.

    Nodal Response to Neoadjuvant Chemotherapy is a Better Predictive Factor of Survival Than Miller-Payne Scoring in Breast Cancer - Authors: Ak, Naziye, et al. - Journal: Journal of Oncological Sciences, 7.2: 42-49

    Evaluation of Prognostic and Predictive Values of Hemogram Parameters in Patients with Advanced Stage Ovarian Carcinoma - Authors: Ak, Naziye, et al. - Journal: Turkish Journal of Oncology/Türk Onkoloji Dergisi, 2021, 36.4

    Identifying Risk Factors Associated with Survival and Drug-Related Toxicities in Imatinib-Resistant Gastrointestinal Stromal Tumor (GIST) Patients Treated with Sunitinib - Authors: Ferhatoglu, F., Karabulut, S., Paksoy, N., & Tastekin, D.

    Real-life Outcomes of ROS1 Fusion-positive Metastatic Lung Cancer Patients who were Treated with Crizotinib - Authors: Dogan, İ., Khanmammadov, N., Paksoy, N., Ferhatoglu, F., Aydın, E., Vatansever, S., & Aydine, A. - Journal: TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY

    Predictors of the acquisition of T790M mutation in EGFR-mutant metastatic lung cancer patients who were treated with EGFR inhibitors - Authors: Dogan, I., Khanmammadov, N., Paksoy, N., Vatansever, S., Saip, P., & Aydıner, A. - Journal: Eurasian Journal of Pulmonology

    Laterality of Adrenal Gland Metastasis in Lung Cancer: Results of a Comparative Study - Authors: Ferhatoglu, F., Gagatay, T., Okumus, G., Aydiner, A., Paksoy, N., Ak, N., ... & Saip, P. - Journal: Eurasian Journal of Medical Investigation, 7(2)

    Poor Risk Factors Affecting Cancer Patients Infected with Covid-19: A Retrospective Comparative Study from a Pandemic Hospital - Authors: Ferhatoglu, F., Kapağan, T., Paksoy, N., Ak, N., Medetalibeyoğlu, A., Şenkal, N., ... & Vatansever, S. - Journal: Turk Onkoloji Dergisi, 38(1)

    Systemic Treatment Outcomes of Progressive Medullary Thyroid Carcinoma from the Registries of a Tertiary Cancer Center - Authors: Ferhatoglu, F., Paksoy, N., & Başaran, M. - Journal: Namik Kemal Tip Dergisi, 10(4)

    Evaluation of clinical features and risk factors related to late recurrence (> 5 years) in patients with breast cancer - Authors: Ferhatoglu, F., Aydiner, A., & Paksoy, N. - Journal: Journal of Surgery & Medicine (JOSAM), 6(12)

    Assessing the Clinical Impact of Lutetium-177 DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) on Metastatic Neuroendocrine Tumors: A Multicenter Real-World Data from Türkiye

     

    Thesis:

    Istanbul University Cerrahpaşa Medical Faculty, Internal Medicine Department PAKSOY, Nail. Demographical, clinical characteristics and survival factors in patients withprimary glomerulonephritis: Cerrahpasa Medical Faculty Experience. (2016)

    International Refereed Congress / Symposium Publications in Proceedings (ASCO/ESMO Abstracts)

    Prognostic factors influencing progression-free survival in HER2 positive metastatic breast cancer patients who treated with lapatinib and capecitabine combination

    • Authors: Dogan, I., Paksoy, N., Ak, N., Vatansever, S., Saip, P., & Aydiner, A. (2022)

    Efficacy of regorafenib and 5-fluorouracil-based rechallenge treatment in the third-line treatment of metastatic colorectal cancer: A Turkish oncology group study

    • Authors: Şenocak Taşçi, E., Oyan, B., Sonmez, O., Mutlu, A. U., Atcı, M. M., Oner, I., ... & Gulmez, A. (2022)

    Long-term outcomes and predictors of recurrence in patients with early-stage node-negative breast cancer

    • Authors: Dogan, I., Aydin, E., Paksoy, N., Ferhatoglu, F., Ak, N., Ibis, K., ... & Aydiner, A. (2021)

    Efficacy of temozolomide in pretreated patients with metastatic sarcoma

    • Authors: Paksoy, N., Dogan, I., Ekenel, M., & Basaran, M. (2021)

    Efficacy of sorafenib in symptomatic patients with pretreated progressive desmoid tumors

    • Authors: Ferhatoglu, F., Paksoy, N., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M. (2021)

    Efficacy of sorafenib in heavily pretreated adult patients with metastatic osteosarcoma

    • Authors: Paksoy, N., Dogan, I., Ekenel, M., & Basaran, M. (2021)

    Outcomes and prognostic factors in metastatic renal cell carcinoma patients with brain metastases

    • Authors: Dogan, İ., Iribas, A., Paksoy, N., Ekenel, M., Vatansever, S., & Basaran, M. (2021)

    Association of response to first-line chemotherapy with the efficacy of atezolizumab in patients with metastatic urothelial carcinoma

    • Authors: Tural, D., Olmez, O. F., Sümbül, A. T., Artac, M., Ozhan, N., Akar, E., ... & Erman, M. (2021)

    Safety and survival in adult women with platinum-sensitive relapsed BRCA mutant ovarian cancer: A study of patients in Olaparib Turkey Early Access Program—LynTurk study

    • Authors: Esin, E., Ahmed, M. A., Yıldırım, H. Ç., Mandel, N. M., Erdemoglu, E., Sari, M., ... & Paydas, S. (2023)

    Atezolizumab in patients with metastatic urothelial carcinoma who have progressed after first-line chemotherapy: Results of real-life experiences

    • Authors: Tural, D., Ölmez, Ö. F., Sümbül, A. T., Artaç, M., Özhan, N., Akar, E., ... & Kılıçkap, S. (2021)

     

     

  • 続きを読む
診察
お問い合わせください
情報

Irfan Cicin

  • 5 優秀 1 レビュー
  • 29年の経験
  • トルコ, イスタンブール, İstinye University Liv Hospital Topkapı
  • Dr. Irfan Cicin is a Professor of Medical Oncology at the Trakya University Faculty of Medicine (2015–present). He has over 20 years of medical oncology experience and has held academic roles since 2010.

    Education: MD, Istanbul University – Cerrahpaşa (1991–1997). Residency in Internal Medicine, Trakya University (1997–2002). Fellowship in Medical Oncology, Trakya University (2002–2004).

    Practice: Medical Oncologist, Trakya University (2005–2008). Medical Oncologist, Elazığ Training and Research Hospital (2008–2010). Associate Professor of Medical Oncology, Trakya University (2010–2015). He previously served as a physician in the Turkish Air Force at Etimesgut Military Hospital (2004–2005).

  • 続きを読む
診察
お問い合わせください
情報

Muhammed Mustafa Atci

  • 5 優秀 1 レビュー
  • 15年の経験
  • トルコ, イスタンブール, İstinye University Liv Hospital Topkapı
  • Dr. Muhammed Mustafa Atci is an Associate Professor of Medical Oncology at İstinye University, Liv Hospital Topkapı (2025–present). He previously served as Associate Professor and Education Coordinator at Prof. Dr. Cemil Taşcıoğlu City Hospital (2023–2025). He was also a Medical Oncologist there (2018–2021).

    He has been a member of ASCO and the Turkish Society of Medical Oncology since 2018. He is the author or co-author of 19 peer-reviewed international papers on colon, breast, gastric, pancreatic, lung, thyroid, sarcoma, and colorectal cancers.

    Notable works include a multicentre study on stage IIB colon cancer survival (Journal of Chemotherapy). He also studied the De Ritis ratio for lung metastasis in testicular cancer (Current Urology). His prognostic studies used PET/CT, MSI, lymph node ratio, and metabolic tumor volume.

  • 続きを読む
診察
お問い合わせください
情報

Ayse Irem Yasin

  • 5 優秀 3 レビュー
  • 15年の経験
  • トルコ, イスタンブール, Medipol Acibadem District Hospital
  • Assoc. Prof. Ayşe İrem Yasin, M.D., is a medical oncologist who specializes in solid tumors. Her clinical focus includes breast, lung, gastrointestinal, gynecologic, and urologic cancers. She also treats brain and other CNS tumors, soft tissue sarcomas, head and neck cancers, adenocarcinomas, melanoma, Merkel cell carcinoma, and cancers of unknown primary. She practices at Medipol Acıbadem District Hospital (2025–present). She previously worked at Şişli Etfal Training and Research Hospital (2023–2025).

    She completed a Medical Oncology fellowship at Bezmialem Vakıf University (2019–2022). This followed an Internal Medicine residency at the same institution (2012–2016). Her international experience includes the Breast Cancer Unit at the University of Piemonte Orientale in Novara (2022). She also trained at Basel University Hospital, Cleveland Clinic, and Harvard Medical School. She holds the ESMO Board Certificate (2022).

  • 続きを読む
診察
お問い合わせください
情報

Muhammed Gomec

  • 5 優秀 1 レビュー
  • 17年の経験
  • トルコ, スィヴァス, Medicana Sivas Hospital
診察
お問い合わせください
情報

Alandag Celal

  • 5 優秀 1 レビュー
  • 17年の経験
  • トルコ, スィヴァス, Medicana Sivas Hospital
診察
お問い合わせください
情報

適切な医師とクリニックの選び方:内部者のヒント

医師やクリニックを選ぶ際は、これらの重要なポイントを覚えておいてください:
資格を確認
ISAPS、JCI、または関連医学会などの機関からの認証を確認してください
成功率を確認
お客様の特定治療に豊富な経験と実績のある医師をお選びください
患者レビューを読む
実際の患者様のBookimedレビューをご覧になり、体験について学んでください
効果的なコミュニケーションの確保
円滑な治療のため言語サポートを提供するクリニックを選んでください。
サービスについて質問
隠れた費用を避けるため、価格に宿泊、現地送迎、アフターケアなどのサービスが含まれているかご確認ください
海外のクリニックを選ぶことはストレスフルです。800,000名以上の患者をサポートしたBookimedは、お客様の懸念を理解しています。信頼できる医師、最高の価格品質オプション、複雑なケースの解決策を見つける方法を知っています。すべての段階でお客様をご案内いたします。
ヤン・マツィイフスキー
医療コーディネーターチーム責任者

Bookimed洞察:トルコのトップ前立腺癌に対する免疫療法専門家(2026)

Bookimedはトルコの前立腺癌に対する免疫療法リクエスト54602件を調整し、21名のトップ評価専門家と協力しています。この表の医師は国際的資格、臨床専門知識、患者の結果に基づいて選ばれています。2026年ランキングは実際の患者ケースとパートナークリニックの現行プログラムからの検証済みデータを使用して形成されています
順位医師経験適合する方特色クリニックと所在地診察
#121年の経験前立腺癌免疫療法トルコの腫瘍内科専門医試験で第3位を獲得し、国際的な研究経験を有する。主要病院の腫瘍内科部門を統括した。
トルコ
から $215
#220年の経験前立腺癌免疫療法前立腺癌免疫療法を専門とし、MDアンダーソンがんセンターにて研鑽を積む。ハジェッテペ大学においてフェローシップを修了し、各種悪性腫瘍の診療に精通する。
トルコ
から $100
#329年の経験前立腺癌に対する免疫療法泌尿生殖器系悪性腫瘍を専門とし、腫瘍学分野において13年以上の集中的な臨床経験を有する。トルコにおける腫瘍学の主要施設であるチェラフパシャ医学部にて研鑽を積んだ。
トルコ
から $215
#422年の経験前立腺癌に対する免疫療法ESMO認定専門医であり、がん免疫療法における高度な専門的研修を修了。多数の論文を発表し、『Handbook of Advanced Cancer Care Treatment』の共著者でもある。
トルコ
から $215